1[1] Enstron JE, Austin DF. Interpreting cancer survival rate[J]. Science, 1997;1:847-850.
2[2] Spain RC. Neoadjuvant mitomycin C, cisplatin and infusion, vinblastine in locally and regionally advanced non-small cell lung cancer: Problems and progress from the perspective of long-term follow-up[J]. Semi Oncol, 1988;15:6-15.
3[3] Blanke C, Ansari R, Mantravadi R et al. Phase Ⅲ trail of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small cell lung cancer: A hoosier oncology group plotocol [J]. J Clin Oncol， 1995;13(6):1425-1429.
4[4] Wagner HJ. Radiation therapy in the management of patients with unresectable stage ⅢA and ⅢB non-small cell lung cancer[J]. Semin Oncol， 1997;24(4):423-428.
5[5] Tejedor M, Valerdi JJ, Lopez R et al. Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage Ⅲ non small cell lung cancer: long-term results[J]. Int J Radiat Oncol Biol Phys，1995;31(4):813-818.
6[6] Dillman RO, Herndon J, Seagren SL et al. Improved survival in stage Ⅲ non-small cell lung cancer: Seven-year follow-up of cancer and leukemia group B(CALGB) 8433 trail[J]. J Natl Cancer Inst, 1996;88(17):1210-1215.
7[7] Alberto P, Mirimanoff RO, Mermillod B et al. Rapidly alternating combination of cisplatin based chemotherapy and hyperfractionated acceterated radiotherapy in split course for stage ⅢA and ⅢB non-small cell lung cancer: Results of a phase Ⅰ/Ⅱstudy by the GOTHA group[J]. Eur J Cancer， 1995;31(3):342-348.
8[8] Hspanhol V,Queiroga H,Magalhaes A et al. Survival predictors in advanced non-small cell lung cancer[J]. Lung Cancer, 1995;13(3):253-267.
2Simpson K,Spenecr CM,McClellan KJ.Tropisetro:An update of its use in the prevention of chemotherapy-induced nausea and vomiting[J].Drugs,2000,59(6):1297.
